These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11812075)

  • 1. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research.
    Perez-Gracia JL; Carrasco EM
    Gynecol Oncol; 2002 Feb; 84(2):201-9. PubMed ID: 11812075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal therapy in epithelial ovarian cancer.
    Rao GG; Miller DS
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):43-7. PubMed ID: 16375643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.
    Love RR; Duc NB; Allred DC; Binh NC; Dinh NV; Kha NN; Thuan TV; Mohsin SK; Roanh le D; Khang HX; Tran TL; Quy TT; Thuy NV; Thé PN; Cau TT; Tung ND; Huong DT; Quang le M; Hien NN; Thuong L; Shen TZ; Xin Y; Zhang Q; Havighurst TC; Yang YF; Hillner BE; DeMets DL
    J Clin Oncol; 2002 May; 20(10):2559-66. PubMed ID: 12011136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
    Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
    Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing patients on endocrine therapy: focus on quality-of-life issues.
    Whelan TJ; Pritchard KI
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1056s-1060s. PubMed ID: 16467124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
    Hilsenbeck SG; Osborne CK
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.
    Paleari L; Gandini S; Provinciali N; Puntoni M; Colombo N; DeCensi A
    Gynecol Oncol; 2017 Sep; 146(3):504-513. PubMed ID: 28705409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
    George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
    BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal adjuvant endocrine therapy for early breast cancer.
    Stuart-Harris R; Davis A
    Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.